Prescription Drug User Fee Act reauthorization.
Diabetes drugs issues.
H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
"Track and trace" issues.
Diabetes research issues.
Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Duration: April 15, 2007
to
December 31, 2012
General Issues: Pharmacy , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Health Issues , Copyright/Patent/Trademark , Veterans , Budget/Appropriations , Science/Technology
Spending: about $980,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS),, Centers For Medicare and Medicaid Services (CMS), House of Representatives,, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA),, Executive Office of the President (EOP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Anne Marie Polak
Leg. Correspondent for Rep. Mike Ferguson
Leg. Correspondent for Cong. Mike Ferguson
Oscar Ramirez
Special Asst. to the Secretary, Dept. of Labor
Chief of Staff, Rep. Hilda Solis
Leg. Director/Deputy CoS, Rep. Al Green
Leg. Asst./Asst. LD/LD, Rep. Joe Baca
Jaime Harrison
Floor Ops. Dir. & Counsel, H. Majority Whip
Executive Director, House Democratic Caucus
Policy Adviser, Rep. James Clyburn
Israel Klein
Dpty. SD/Communications, Jt. Economic Cmte.
Press Secy/LA/Sr. Comm. Adv, Rep. Ed Markey
Comm. Director, Sen. Charles Schumer
Paul Brathwaite
Exec. Dir., Congressional Black Caucus
Executive Director Congressional Black Caucus
DOL Special Assistant to Secretary of Labor
DOL Emplm'nt Standards Administration (ESA)
DOT, General Counsel's Honors Program
Tom Sparkman
Health Policy Intern, Senate HELP Committee
Steve Northrup
Health Policy Director, Sen. Michael Enzi
Lantie Slenzak
Legislative Director, Rep. Gene Green
Sharon Cohen
n/a
Thomas Sparkman
n/a
Anthony Podesta
n/a
Claudia James
n/a
Stephen Northrup
n/a
Cristina Antelo
n/a
Christina Antelo
n/a
Daniele Baierlein
n/a
Courtney Hagen
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2012
PODESTA GROUP, INC. terminated an engagement in which they represented Bristol-Myers Squibb on Jan. 22, 2013.
Original Filing: 300542673.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Diabetes drugs issues.
H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
"Track and trace" issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
H.R. 6684, Spending Reduction Act of 2012.
H.R. 8, American Taxpayer Relief Act of 2012.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2012
In Q3, PODESTA GROUP, INC. lobbied for Bristol-Myers Squibb (formerly Amylin Pharmaceuticals, Inc.) , earning $50,000. The report was filed on Oct. 22, 2012.
Original Filing: 300518149.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Diabetes drugs issues.
H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act.
H.R. 6433, FDA User Fee Corrections Act of 2012.
"Track and trace" issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on July 19, 2012.
Original Filing: 300491872.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
Diabetes drugs issues.
H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act.S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act
"Track and trace" issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Food & Drug Administration (FDA)
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on April 19, 2012.
Original Filing: 300468818.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues.
Diabetes drugs issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2011
In Q4, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Jan. 20, 2012.
Original Filing: 300446774.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues.
Diabetes drugs issues.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Diabetes issues.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.
H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes issues.
H.R. 2055 and H.R. 3671, Consolidated Appropriations Act of 2011, Pub. L. 112-74.
H.J.RES. 95, Continuing Resolution through 12/23/11, Pub. L. 112-68.
H.J.RES. 94, Continuing Resolution through 12/17/11, Pub. L. 112-67.H.R. 2608, Continuing Appropriations Act, 2012, Pub. L. 122-36.
H.R. 3070 / S. 1599, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2012.
H.R. 3765, Temporary Payroll Tax Cut Continuation of 2011, Pub. L. 112-78.
H.R. 3630, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 3743, Middle Class Tax Relief and Job Creation Act of 2011.
H.R. 2112, Consolidated and Further Continuing Appropriations Act, 2012, Pub. L. 112-055.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2011
In Q3, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Oct. 20, 2011.
Original Filing: 300425685.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues.
Diabetes drugs issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Diabetes research issues.
Monitor debt ceiling negotiations.
H.R. 1599, Labor-HHS Appropriations.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Monitor debt ceiling negotiations.
Diabetes issues.H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.
S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Diabetes issues.
Monitor debt ceiling negotiations.
H.R. 2017, Continuing Appropriations Act, 2012.
H.R. 2608, Continuing Appropriations Act, 2012.S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2011
In Q2, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on July 20, 2011.
Original Filing: 300400965.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues, generally.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Diabetes research issues.
Debt Ceiling (not bill yet, just the topic)
HR 1473 Department of Defense and Full-year Continuing Appropriation Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Debt Ceiling (not bill yet, just the topic)
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Diabetes issues, generally.
Patient Protection and Affordable Care Act implementation.
Monitor debt ceiling negotiations.
H.R. 1473, Department of Defense and Full-Year Continuing Appropriations Act of 2011
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2011
PODESTA GROUP, INC. amended a lobbying report for representation of Amylin Pharmaceuticals, Inc. in Q12011 on May 24, 2011.
Original Filing: 300384476.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues, generally.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Diabetes issues, generally.
Patient Protection and Affordable Care Act implementation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on April 20, 2011.
Original Filing: 300374280.xml
Lobbying Issues
Prescription Drug User Fee Act reauthorization.
FDA issues, generally.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Diabetes research issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare coverage and reimbursement issues.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
H.R. 1249/S. 23, America Invents Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Diabetes issues, generally.
Patient Protection and Affordable Care Act implementation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Jan. 20, 2011.
Original Filing: 300353144.xml
Lobbying Issues
Drug Importation/Drug Safety
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS),
Lobbying Issues
Diabetes Research Issues, Comparative Effectiveness Research
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 4213 American Jobs and Closing Tax Loopholes Act of 2010H.R. 3081 Continuing Appropriations Act, 2011
H.R. 4994, Medicare and Medicaid Extenders Act of 2010; P.L. 111-309
H.R. 5712, The Physician Payment and Therapy Relief Act of 2010; P.L. 111-286
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 5322 Patent and Trademark Office Funding Stabilization Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act implementation
P.L. 111-152 Health Care and Education Reconciliation Act of 2010 implementation
H.R. 3082, Continuing Appropriations and Surface Transportation Extensions Act, 2011; PL 111-322
H.J.RES.105, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-317H.J.RES.101, Making further continuing appropriations for fiscal year 2011, and for other purposes; PL 111-290
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives,
3rd Quarter, 2010
In Q3, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Oct. 19, 2010.
Original Filing: 300321557.xml
Lobbying Issues
Drug Importation/Drug Safety
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
S. 3677 Financial Services and General Government Appropriations Act, 2011 (Pay to Delay Provision)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS),
Lobbying Issues
Diabetes Research Issues, Comparative Effectiveness Research
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
H.R. 4213 American Jobs and Closing Tax Loopholes Act of 2010H.R. 3081 Continuing Appropriations Act, 2011 (340B Provisions)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 5322 Patent and Trademark Office Funding Stabilization Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
P.L. 111-148 Patient Protection and Affordable Care Act
P.L. 111-152 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives,
2nd Quarter, 2010
In Q2, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on July 19, 2010.
Original Filing: 300293247.xml
Lobbying Issues
Drug Importation/Drug Safety
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS),
Lobbying Issues
Diabetes research issues
Comparative effectiveness
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 American Jobs and Closing Tax Loopholes Act of 2010H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
H.R. 3962 Preservation of Access to Care for Medicare Beneficiaries and Pension Relief Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
H.R. 5322 Patent and Trademark Office Funding Stabilization Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Agencies Lobbied
U.S. House of Representatives,
1st Quarter, 2010
In Q1, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on April 15, 2010.
Original Filing: 300259294.xml
Lobbying Issues
Drug Importation/Drug Safety
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS),
Lobbying Issues
Diabetes research issues
Comparative effectiveness
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
H.R. 4213 Workers, State, and Business Relief Act of 2010H.R. 2847 Hiring Incentives to Restore Employment Act
H.R. 4851 Continuing Extension Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 Health Care and Education Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Jan. 15, 2010.
Original Filing: 300233101.xml
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Drug Importation/Drug Safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA),
Lobbying Issues
H.R. 3288 Consolidated Appropriations Act, 2010, LHHS - Division D
Diabetes research issues
Comparative effectiveness
H.R. 2502 Comparative Effectiveness Research Act of 2009S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
S. 1679 Affordable Health Choices Act
H.R. 3200 American Health Choices Act of 2009Tri Caucus Healthcare Reform Bill
S. 1796 Americas Healthy Future Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
H.R. 3288 Consolidated Appropriations Act, 2010, LHHS - Division D
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
S. 1679 Affordable Health Choices Act
H.R. 3200 American Affordable Health Choices Act of 2009
Tri Caucus Healthcare Reform BillS. 1796 Americas Healthy Future Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
H.R. 3962 Affordable Health Care for America Act
H.R. 3590 Patient Protection and Affordable Care Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Oct. 17, 2009.
Original Filing: 300208709.xml
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Drug Importation/Drug Safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA),
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
H.R. 2502 Comparative Effectiveness Research Act of 2009S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Kennedy American Health Choices Act of 2009
H.R. 3200 American Health Choices Act of 2009Tri Caucus Healthcare Reform Bill
Baucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Kennedy American Affordable Health Choices Act of 2009
H.R. 3200 American Affordable Health Choices Act of 2009
Tri Caucus Healthcare Reform BillBaucus/Finance Healthcare Reform Bill - America's Healthy Future Act of 2009
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
S. 301 Physician Payments Sunshine Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on July 17, 2009.
Original Filing: 300183804.xml
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 1548 Pathway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Drug Importation/Drug Safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA),
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
H.R. 2502 Comparative Effectiveness Research Act of 2009S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Medicare Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform BillTri Caucus Healthcare Reform Bill
Senate Finance Healthcare Reform Bill
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
S. 610 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
S. 1110 Medicare Payment Advisory Commission (MedPAC) Reform Act of 2009
Kennedy Healthcare Reform Bill
House Tri Committee Healthcare Reform Bill
Tri Caucus Healthcare Reform BillSenate Finance Healthcare Reform Bill
H.R. 2502 Comparative Effectiveness Research Act of 2009
S. 1213 Patient-Centered Outcomes Research Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on April 19, 2009.
Original Filing: 300155845.xml
Lobbying Issues
H.R. 1427 Promoting Innovation and Access to Life-Saving Medicine Act
H.R. 1548 Pathyway for Biosimilars Act
S. 726 Promoting Innovation and Access to Life-Saving Medicine Act
Drug Importation/Drug Safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA),
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
H.R. 1260 Patent Reform Act of 2009
S. 515 Patent Reform Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1 American Recovery and Reinvestment Act of 2009
S. Con. Res. 13
H. Con. Res. 85
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Jan. 21, 2009.
Original Filing: 300128600.xml
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Drug importation
H.R. 5629, Pathway for Biosimilars Act
H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Executive Office of the President (EOP)
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
H.R. 1424, Emergency Economic Stabilization Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H. R. 1908, Patent Reform Act of 2007, entire bill
S. 3600, Patent Reform Act of 2008, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Comparative EffectivenessFDA/drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on Oct. 17, 2008.
Original Filing: 300099864.xml
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Drug importation
H.R. 5629, Pathway for Biosimilars Act
H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Executive Office of the President (EOP)
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
H.R. 1424, Emergency Economic Stabilization Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H. R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Comparative EffectivenessFDA/drug importation issues
H.R. 2638, Consolidated Security, Disaster Assistance, and Continuing Appropriations Act, 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $50,000. The report was filed on July 20, 2008.
Original Filing: 300076195.xml
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Drug importation
H.R. 5629, Pathway for Biosimilars Act
H.R. 5839, Safeguarding America's Pharmaceuticals Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Executive Office of the President (EOP)
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
H.R. 6331, Medicare Improvements for Patients and Providers Act of 2008
S. 3101, Medicare Improvements for Patients and Providers Act of 2008
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H. R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Comparative EffectivenessFDA/drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, PODESTA GROUP, INC. lobbied for Amylin Pharmaceuticals, Inc. , earning $30,000. The report was filed on April 16, 2008.
Original Filing: 300038496.xml
Lobbying Issues
H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics
H. R. 1561, Enhancing Drug Safety and Innovation Act of 2007, drug safety provisions
H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics
S. 1505, Affordable Biologics for Consumers Act, follow-on biologics
S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics
S. 2029, Physician Payments Sunshine Act of 2007
S. 596, Safe Internet Pharmacy Act of 2007, clinical trials/drug safety provisions
S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Drug importation
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS) Food & Drug Administration (FDA) Executive Office of the President (EOP)
Lobbying Issues
LHHS appropriations
Diabetes research issues
Comparative effectiveness
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
H. R. 2606, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
H. R. 3162, Children's Health and Medicare Protection Act of 2007
H. R. 4, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
H. R. 5480, Medicare Funding Warning Response Act of 2008S. 1376, 340B Program Improvement and Integrity Act of 2007, 340B drug price expansion
S. 2029, Physician Payments Sunshine Act of 2007
S. 2662, Medicare Funding Warning Response Act of 2008
S. 3, Medicare Prescription Drug Price Negotiation Act, Medicare "non-interference" provisions
SCHIP (Senate), Medicare cuts to finance SCHIP expansion
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
S. 1145, Patent Reform Act of 2007, entire bill
H. R. 1908, Patent Reform Act of 2007, entire bill
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
FY09 Administration Budget
House Concurrent Resolution 312 FY09 Revised Congressional Budget
Senate Concurrent Resolution 70 FY09 Congressional Budget
Comparative EffectivenessFDA/drug importation issues
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2007
PODESTA GROUP, INC. filed a lobbying registration on May 29, 2007 to represent Amylin Pharmaceuticals, Inc., effective April 15, 2007.
Original Filing: 200037267.xml
Issue(s) they said they’d lobby about: FDA/PDUFA Reauthorazation, Medicare and Patent Reform, VA Healthcare, Science/Technoloy issues. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate